The proteasome inhibitor carfilzomib is a promising new agent for the treatment of multiple myeloma (MM). Data presented at the 53rd Annual Meeting of the American Society of Hematology (ASH) highlighted a role for this agent in both the frontline and relapsed and/or refractory settings.